340B Studies and AHA Responses

A number of studies – many paid for and supported by the pharmaceutical industry – have come out in recent years examining the 340B drug savings program. The AHA has responded to a number of these studies attempting to set the record straight on the 340B program.

Study

AHA Responses
Drug Pricing Proposals That Focus on 340B Miss Mark (February 22, 2018)
What the Authors of a Recent Study Would Have Learned about the 340B Program Had They Asked (February 9, 2018)
Major Methodological Flaws Negate Findings from Recent 340B Study (February 5, 2018)
Report Misleads on Drug Prices (October 19, 2017)
Report misses mark on 340B program (October 10, 2017)
Changing 340B is the wrong prescription for addressing skyrocketing pharmaceutical costs (March 8, 2016)
AHA: GAO report on 340B program misses the mark (July 9, 2015)
AHA Responds to Latest Effort by Pharmaceutical Industry to Disparage 340B Program (June 9, 2015)
Setting the Record Straight on 340B (December 8, 2014)
Health Affairs Study Gets It Wrong on 340B (October 6, 2014)

Related Resources

Case Studies
Johnson County Hospital | Nebraska
Public
Action Alert
TAKE ACTION: Urge Lawmakers to Reject Medicaid Cuts, Protect Access to Care
Member Non-Fed
Case Studies
340B Benefits Patients and Communities: Examples from the Frontlines
Public
Action Alert
Contact Your Lawmakers and Urge Them to Extend Key Health Care Policies Set to Expire Next Month
Member Non-Fed
Fact Sheets
Fact Sheet: 340B Drug Pricing Program Contract Pharmacy Arrangements
Public
Fact Sheets
Fact Sheet: 340B Drug Pricing Program: Fact vs Fiction
Public